Li Yan1, Ming Tong Xu2, Li Yuan3, Bing Chen4, Zhang Rong Xu5, Qing Hua Guo6, Qiang Li7, Yu Duan8, Jian Huang Fu9, Yong Jian Wang10, Miao Zhang11, Zuo Jie Luo12, Wei Gang Zhao13, You Min Wang14, Zhen Fang Yuan15, Wei Qing Wang16, Peng Hua Wang17, Xing Wu Ran18, Yan Jun Wang19, Hua Zhang Yang20, Ling Gao21, Wei Qing Chen22, Guang Ning23. 1. Department of Endocrinology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China. Electronic address: hfxyl@163.net. 2. Department of Endocrinology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China. 3. Department of Endocrinology, Union Hospital, Huazhong University of Science and Technology, Wuhan, China. 4. Department of Endocrinology, Southwest Hospital, Third Military Medical University, Chongqing, China. 5. Department of Endocrinology, Chinese PLA 306 Hospital, Beijing, China. 6. Department of Endocrinology, Chinese PLA General Hospital, Beijing, China. 7. Department of Endocrinology, The Second Affiliated Hospital of Harbin Medical University, Harbin, China. 8. Department of Endocrinology, The First Affiliated Hospital of Nangjing Medical University, Nangjing, China. 9. Department of Endocrinology, Affiliated Hospital of Inner Mongolia Medical University, Huhehaote, China. 10. Department of Endocrinology, The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, China. 11. Department of Endocrinology, Affiliated Hospital of Guiyang Medical College, Guiyang, China. 12. Department of Endocrinology, the First Affiliated Hospital of Guangxi Medical University, Nanning, China. 13. Department of Endocrinology, Chinese Academy of Medical Science & Peking Union Medical College Hospital, Beijing, China. 14. Department of Endocrinology, the First Affiliated Hospital of Anhui Medical University, Hefei, China. 15. Department of Endocrinology, Peking University First Hospital, Beijing, China. 16. Department of Endocrinology and Metabolism, Shanghai Institute of Endocrine and Metabolic Diseases, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China. 17. Department of Endocrinology, 2011 Collaborative Innovation Center of Tianjin for Medical Epigenetics, the Key Laboratory of Hormones and Development (Ministry of Health), Metabolic Diseases Hospital & Tianjin Institute of Endocrinology, Tianjin Medical University, Tianjin, China. 18. Department of Endocrinology and Metabolism, West China Hospital, Sichuan University, Chengdu, China. 19. Department of Endocrinology, Shengjing Hospital of China Medical University, Shenyang, China. 20. Department of Endocrinology, Guangdong General Hospital, Guangzhou, China. 21. Department of Endocrinology, Provincial hospital Affiliated to Shandong University, Jinan, China. 22. Department of Medical Statistics and Epidemiology, School of Public Health, Sun Yat-sen University, Guangzhou, China. Electronic address: chenwq@mail.sysu.edu.cn. 23. Department of Endocrinology and Metabolism, Shanghai Institute of Endocrine and Metabolic Diseases, Ruijin Hospital, Shanghai Jiao tong University School of Medicine, Shanghai, China. Electronic address: gning@sibs.ac.cn.
Abstract
OBJECTIVE: The aim of this study was to assess the levels of serum lipid and awareness, treatment, and control of dyslipidemia in type 2 diabetes mellitus (T2DM) patients from top-ranked endocrinology clinics in large cities of China. MATERIALS AND METHODS: A cross-sectional study in a representative sample of 4807 Chinese adults 40 to 75 years of age was conducted during 2010 to 2011 at 20 endocrinology clinics in top-ranked hospitals covering most of the major cities of China. Serum lipid levels were measured, and treatment of dyslipidemia was recorded and assessed. RESULTS: In the present study, the prevalence of dyslipidemia was 67.1% in T2DM subjects. Among those with dyslipidemia, the proportion of awareness and treatment was 68.7% and 55.9%. Among participants with lipid-lowering therapy, 686 subjects achieved the low-density lipoprotein cholesterol (LDL-C) control less than 2.60 mmol/L, with the rate being 39.4%. In those patients with previous cardiovascular disease, the percentage of participants who achieved LDL-C goal (1.80 mmol/L) was 15.3%. CONCLUSION: The prevalence of dyslipidemia is high, and the awareness, treatment, and control of dyslipidemia are relatively low in Chinese T2DM patients. This calls for the awareness and intervention of dyslipidemia in these patients.
OBJECTIVE: The aim of this study was to assess the levels of serum lipid and awareness, treatment, and control of dyslipidemia in type 2 diabetes mellitus (T2DM) patients from top-ranked endocrinology clinics in large cities of China. MATERIALS AND METHODS: A cross-sectional study in a representative sample of 4807 Chinese adults 40 to 75 years of age was conducted during 2010 to 2011 at 20 endocrinology clinics in top-ranked hospitals covering most of the major cities of China. Serum lipid levels were measured, and treatment of dyslipidemia was recorded and assessed. RESULTS: In the present study, the prevalence of dyslipidemia was 67.1% in T2DM subjects. Among those with dyslipidemia, the proportion of awareness and treatment was 68.7% and 55.9%. Among participants with lipid-lowering therapy, 686 subjects achieved the low-density lipoprotein cholesterol (LDL-C) control less than 2.60 mmol/L, with the rate being 39.4%. In those patients with previous cardiovascular disease, the percentage of participants who achieved LDL-C goal (1.80 mmol/L) was 15.3%. CONCLUSION: The prevalence of dyslipidemia is high, and the awareness, treatment, and control of dyslipidemia are relatively low in Chinese T2DM patients. This calls for the awareness and intervention of dyslipidemia in these patients.